During primary infection with varicella-zoster virus (VZV), a diffuse vesicular rash develops as VZV enters the bloodstream, leading to seeding of sensory nerve ganglia and establishment of a reservoir of latent VZV \[[@CIT0001], [@CIT0002]\]. From this reservoir, reactivation can occur in the form of herpes zoster (HZ) \[[@CIT0001], [@CIT0002]\]. HZ typically manifests as a painful rash following the distribution of 1 or more sensory nerves, usually developing decades after primary infection \[[@CIT0001], [@CIT0002]\]. Although the pain of acute HZ itself can be severe and result in hospitalization, a dreaded complication of HZ is post-herpetic neuralgia (PHN), which can persist for months to years, potentially resulting in marked debilitation and reduced quality of life \[[@CIT0001], [@CIT0002]\].

The risk of HZ and PHN increases with age as the level of T-cell immunity declines with immunosenescence \[[@CIT0001], [@CIT0002]\]. This risk also increases in immunocompromised persons with impaired T-cell immunity, including those infected with HIV, recipients of immunosuppressive therapy after organ or stem cell transplant, recipients of other forms of immunosuppressive therapy, and those with lymphoma or leukemia \[[@CIT0002]\]. HZ develops in up to 50% of unvaccinated individuals who live to 85 years of age, and there are more than 1 million cases of HZ in the United States each year \[[@CIT0001], [@CIT0002]\]. The direct medical cost burden of HZ infection in the United States has been estimated to possibly exceed \$1 billion annually \[[@CIT0003]\].

A live attenuated Oka strain varicella-zoster vaccine (LAV; Zostavax, Merck & Co., inc., Whitehouse Station, NJ \[Merck\]) was approved by the Food and Drug Administration (FDA) in 2006 for the prevention of HZ for persons 60 years of age or older \[[@CIT0001]\]. In 2008, it was recommended by the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) for this indication \[[@CIT0002]\]. Notably, the efficacy of LAV to prevent HZ decreases with age, from \~70% efficacy for persons 50--59 years of age to 64% for persons 60 to 69 years of age, and down to approximately 37% for persons 70 years of age or older \[[@CIT0002], [@CIT0004], [@CIT0005]\]. Injection site reactions (ISRs) were generally mild \[[@CIT0002], [@CIT0005]\], and LAV efficacy was found to wane in the Long-Term Prevention Study (LTPS) \[[@CIT0006]\]. More recently, LAV was FDA approved in persons 50 years of age or older \[[@CIT0002]\]; however, in 2014, the ACIP elected to leave its age recommendation unchanged, in part based upon an unpublished cost-effectiveness analysis (CEA) \[[@CIT0007]\].

In October 2017, the FDA approved an HZ subunit vaccine (SUV) containing recombinant varicella-zoster virus glycoprotein E and the AS01~B~ adjuvant system for the prevention of HZ in people aged 50 years and older (Shingrix, GlaxoSmithKline Biologicals, Research Triangle Park, NC \[GSK\]) \[[@CIT0008]\]. SUV was studied as a 2-dose series administered 2 months apart in 2 randomized, placebo-controlled trials, ZOE-50 (adults 50 years of age and older) and ZOE-70 (adults 70 years of age and older), demonstrating 96.2% and 87.7% efficacy at reducing the risk of HZ in the total vaccinated cohorts, respectively \[[@CIT0009], [@CIT0010]\]. Pooled analysis for persons 70 years of age and older in ZOE-50 and ZOE-70 demonstrated efficacy of 89.9% against HZ and 78.9% against PHN in the total vaccinated cohort \[[@CIT0010]\]. There were more ISRs and systemic reactions compared with placebo, but serious adverse events occurred with similar frequencies, and 95.5% returned for their second immunization \[[@CIT0009], [@CIT0010]\].

There have been numerous studies that have analyzed cost-effectiveness for LAV in the form of cost per quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio (ICER) compared with no vaccine (NoV), with variable results based on age at vaccination, epidemiology, utility estimates, duration of vaccine protection, and cost of the vaccine \[[@CIT0011]\]. In general, LAV has been found to be effective in preventing HZ and PHN in persons aged 50 years and older; however, it has been most consistently found to be cost-effective in persons aged 60 and above \[[@CIT0011]\].

On January 26, 2018, the ACIP recommended the use of SUV for the prevention of HZ and related complications for immunocompetent adults aged ≥50 years, including those who have previously received LAV \[[@CIT0008]\]. The ACIP stated a preference for SUV over LAV for the prevention of HZ and related complications \[[@CIT0008]\]. These recommendations were in part driven by CEAs by the CDC \[[@CIT0019]\], Le and Rothberg \[[@CIT0020]\], GSK \[[@CIT0021]\], and Merck. Additional independent CEAs are prudent. The following analysis compares the cost-effectiveness of SUV with LAV and a strategy of no vaccine.

METHODS {#s1}
=======

To estimate the cost utility of SUV vs the LAV and no vaccination strategies, a Markov decision model was developed ([Figure 1](#F1){ref-type="fig"}) based on published randomized controlled trials and data on vaccine efficacy, durability of protection, quality of life, resource utilization, costs, and disease epidemiology, utilizing Microsoft Excel 2016 (Microsoft Corporation). The target population was stratified by age, allowing entry into the model at age 50 years or older, and data were modeled until the last cohort member was assumed to have died at age 100 years. The cycle length was 1 year, with a lifelong time horizon, and data for men and women were modeled together. The CEA took a societal perspective in its cost and utility assessments, with both costs (in 2018 US dollars) and QALYs discounted at 3% per year, and it was structured to allow comparisons based on 3 vaccination strategies: SUV, LAV, and NoV.

![Four state Markov model structure. No Vaccination, Subunit Vaccination, and Live Attenuated Vaccine differ in the rates at which individuals transition from the "No Herpes Zoster" state to the "Herpes Zoster" state. The reduction in herpes zoster incidence with vaccination depends on the initial vaccine efficacy (based on age of vaccination) and the number of years since vaccination (where the linear vaccine waning reduces efficacy each year). Abbreviations: HZ, herpes zoster; PHN, post-herpetic neuralgia.](ofz219f0001){#F1}

Individuals entering the model were assumed to be immunocompetent adults at risk for HZ and PHN based upon 2011 US age group risk estimates \[[@CIT0022]\], decreased as appropriate based on the efficacy associated with each vaccine strategy. Modeled complications included PHN, acute ocular involvement, hospitalization, and death. These complications were assumed to be independent, and individuals were returned to the health state "at risk for HZ" unless they died from HZ or other causes. Utility was assumed to be lost for acute ocular complications and PHN for that episode cycle year, and for death utility was lost as a permanent decrement in QALYs. The outcomes included costs (vaccine-associated costs, direct medical costs, and indirect productivity costs) and effectiveness (reductions in HZ cases and PHN cases, increases in QALYs) for each strategy. The ICER was estimated as the incremental cost divided by the incremental change in QALYs of each strategy vs the other strategies.

Model inputs and assumptions for the base case analysis are presented in [Table 1](#T1){ref-type="table"}. Data were derived primarily from studies of the general US population without immune-compromising conditions and include epidemiologic parameters, vaccination parameters, costs, and QALYs \[[@CIT0002], [@CIT0004], [@CIT0005], [@CIT0009], [@CIT0010], [@CIT0014]\]. Age-specific mortality rates were based on 2011 US life tables \[[@CIT0023]\]. Measures of the risk of PHN, degree of severity, and associated loss of utility were derived from Le and Rothberg \[[@CIT0014]\] and from Harvey \[[@CIT0024]\].

###### 

Model Parameters: Epidemiologic Data, Vaccination Efficacy and Adverse Events, Utilities and Costs With Base Case Values, and Ranges Used for Sensitivity Analyses

  Variable                                                          Base Case Value   Range                      Source
  ----------------------------------------------------------------- ----------------- -------------------------- -----------------------------------------------------------------------------
  HZ incidence per 1000 person-years                                                                             Johnson et al. \[[@CIT0022]\], 2015
   50--59 y                                                         6.74              6.66 to 6.82               
   60--69 y                                                         9.32              9.20 to 9.44               
   70--79 y                                                         12.02             11.79 to 12.25             
   80--100 y                                                        12.78             12.49 to 13.07             
  Complications given HZ, %                                                                                      
  Probability of ocular complications                                                                            Harvey \[[@CIT0024]\], 2016
   50--59 y                                                         0.03              0.00 to 0.05               
   60--69 y                                                         0.04              0.02 to 0.06               
   70--79 y                                                         0.05              0.03 to 0.07               
   80--100 y                                                        0.07              0.05 to 0.09               
  PHN by age                                                                                                     Le et al. \[[@CIT0014]\], 2015
   50--59 y                                                         0.038             0.023 to 0.053             
   60--69 y                                                         0.069             0.042 to 0.096             
   70--100 y                                                        0.185             0.142 to 0.228             
  Probability of moderate or severe PHN                                                                          Harvey \[[@CIT0024]\], 2016
   50--59 y                                                         0.46              0.36 to 0.56               
   60--69 y                                                         0.56              0.46 to 0.66               
   70--79 y                                                         0.61              0.51 to 0.71               
   80--84 y                                                         0.65              0.55 to 0.75               
   85--100 y                                                        0.68              0.58 to 0.78               
  Probability of moderate PHN in individuals with mod--severe PHN   0.5               0.03 to 0.08               Harvey \[[@CIT0024]\], 2016
  Probability of pain given HZ                                      0.05              0.00 to 0.27               Harvey \[[@CIT0024]\], 2016
   No pain given HZ                                                 0.11              0.04 to 0.43               
   Mild pain given HZ                                               0.37              0.19 to 0.57               
   Moderate pain given HZ                                           0.47              0.26 to 0.63               
   Severe pain given HZ                                                                                          
  Death due to HZ per 100 000 cases of HZ                                                                        CDC WONDER \[[@CIT0031]\], 2017
   50--59 y                                                         1.26              0.86 to 1.67               
   60--69 y                                                         2.22              1.72 to 2.72               Le et al. \[[@CIT0014]\], 2015
   70--79 y                                                         6.18              5.32 to 7.03               
   80--89 y                                                         23.96             21.88 to 26.03             
   90--100 y                                                        152.13            143.76 to 160.5            
  Vaccination efficacy and adverse events                                                                        
  LAV efficacy                                                      0.698             0.489 to 0.907             Oxman et al. \[[@CIT0005]\], 2005, and Harvey \[[@CIT0024]\], 2016
   50--59 y                                                                                                      
   60--69 y                                                         0.657             0.460 to 0.854             
   70--79 y                                                         0.407             0.285 to 0.529             
   80--100                                                          0.157             0.110 to 0.204             
  LAV waning rate (and assumed SUV waning rate)                     --0.0544          --0.072 to --0.037         Morrison et al. \[[@CIT0006]\], 2015, and Le et al. \[[@CIT0014]\], 2015
  SUV efficacy                                                                                                   Lal et al. \[[@CIT0009]\], 2015, and Cunningham et al. \[[@CIT0010]\], 2016
   Aged 50--59 y                                                    0.969             0.906 to 0.994             
   Aged 60--69 y                                                    0.941             0.856 to 0.981             
   Aged 70--79 y                                                    0.899             0.846 to 0.937             
   Aged 80 y and above                                              0.897             0.786 to 0.958             
  SUV waning rate (2 doses)                                         --0.0544          --0.072 to --0.037         Assumption
  SUV waning rate (1 dose)                                          --0.0800                                     Assumption
  Adverse events above placebo                                                                                   
   LAV injection site reaction                                      0.317             0.283 to 0.326             Morrison et al. \[[@CIT0006]\], 2015
   LAV serious adverse event                                        0.001             0 to 0.002                 Morrison et al. \[[@CIT0006]\], 2015
   SUV injection site reaction                                      0.669             0.6021 to 0.7359           Lal et al. \[[@CIT0009]\], 2015, and Cunningham et al. \[[@CIT0020]\], 2016
   SUV serious adverse event                                        0.00058           0 to 0.003                 Lal et al. \[[@CIT0009]\], 2015, and Cunningham et al. \[[@CIT0010]\], 2016
  Utilities                                                                                                      
  Acute HZ QALYs lost                                                                                            Lieu et al. \[[@CIT0029]\], 2008
   No pain HZ                                                       0.020             0.014 to 0.026             
   Mild HZ                                                          0.041             0.029 to 0.053             
   Moderate HZ                                                      0.047             0.033 to 0.061             
   Severe HZ                                                        0.058             0.040 to 0.075             
   Average Acute HZ QALYs lost                                      0.050                                        
  PHN QALYs lost (1 y)                                                                                           Harvey \[[@CIT0024]\], 2016
   Mild pain PHN                                                    0.31              0.211 to 0.433             
   Moderate pain PHN                                                0.55              0.389 to 0.731             
   Severe pain PHN                                                  0.77              0.498 to 0.992             
  Ocular complications QALYs lost (1 y)                             0.24              0.178 to 0.311             Harvey \[[@CIT0024]\], 2016
  Common adverse reaction QALYs lost per dose                       0.001             0.0005 to 0.002            Harvey \[[@CIT0024]\], 2016
  Serious adverse event QALYs lost per dose                         2.13E-05          6.41E-06 to 4.57E-05       Harvey \[[@CIT0024]\], 2016
  Costs                                                                                                          
   LAV                                                              \$134.16          \$100.62 to \$167.70       CDC (CMS Cost/Dose) \[[@CIT0027]\], 2018
   SUV                                                              \$204.38          \$153.29 to \$255.48       CDC (CMS Cost/Dose) \[[@CIT0027]\], 2018
   Vaccine administration cost (HCPCS 90471)                        \$20.88           \$15.66 to \$26.10         CMS Fee Schedule \[[@CIT0028]\], 2018
   Direct medical costs, \$/case, adjusted for inflation                                                         Harvey \[[@CIT0024]\], 2016
   Acute HZ                                                         \$957             \$867 to \$1051            
   PHN                                                              \$5831            \$4055 to \$7936           
   Ocular complications                                             \$4163            \$2986 to \$5543           
   Serious adverse event                                            \$9778.32         \$5975.64 to \$13 581.00   Dunn et al. \[[@CIT0031]\], 2014
   Productivity costs HZ, h                                                                                      Harvey \[[@CIT0024]\], 2016
   No pain HZ                                                       5                 3 to 6                     
   Mild                                                             6                 4 to 8                     
   Moderate HZ                                                      22                15 to 30                   
   Severe HZ                                                        61                39 to 82                   
   Mild pain, PHN                                                   4                 3 to 5                     
   Moderate pain, PHN                                               30                20 to 41                   
   Severe pain, PHN                                                 81                53 to 110                  
   Average hourly wages                                             \$26.61           \$19.96 to \$33.26         

Abbreviations: CDC, Centers for Disease Control and Prevention; CMS, Centers for Medicare and Medicaid Services; HCPCS, Healthcare Common Procedure Coding System; HZ, herpes zoster; ICER, incremental cost-effectiveness ratio; LAV, live attenuated herpes zoster vaccine; NoV, no vaccine; PHN, post-herpetic neuralgia; QALY, quality-adjusted life-year, SUV, subunit vaccine.

Vaccine efficacy rates were obtained from published randomized controlled trials \[[@CIT0004], [@CIT0008], [@CIT0009]\]. Adherence to the second dose of SUV was 95.5% in the combined data for ZOE-50 and ZOE-70; as such, the efficacy data utilized were from the total vaccinated cohorts to account for reduced efficacy due to the reduced adherence to the second dose \[[@CIT0009], [@CIT0010]\]. The efficacy of LAV over time has been studied in the LTPS for persons aged 60 years and older, with limited long-term efficacy data for persons aged 50 to 59 years \[[@CIT0006]\]. Le and Rothberg, in their cost-effectiveness analysis of HZ for persons aged 50 years, calculated a linear slope waning rate of --0.0544 per year with the assumption that LAV waned at the same rate regardless of age at vaccination, and they utilized this waning rate estimate for SUV \[[@CIT0006], [@CIT0014]\]. We similarly utilized --0.0544 per year as the waning rate for the slope in our model (ie, vaccine efficacy decreased linearly at 5.44% per year) for LAV and after 2 doses of SUV, and we assumed a more rapid waning rate of --0.08 per year when only 1 dose of SUV was received. Prosser, in her economic evaluation of LAV and SUV for the prevention of HZ and related complications, estimated similar waning rates for SUV (--0.0515 per year for both doses and --0.0909 per year for 1 dose) based on data from Cunningham et al. and other assumptions \[[@CIT0010], [@CIT0019]\].

Costs, including those associated with acute HZ, PHN, and other complications, were derived from prior estimates with adjustment to 2018 US dollars \[[@CIT0024]\]. As of June 1, 2018, the CDC listed its vaccine contract price for LAV at \$134.16, and the initial CDC vaccine contract price for SUV was \$102.19 per dose or \$204.38 total for both doses \[[@CIT0027]\]. Immunization administration cost was \$20.88 per dose based on the 2018 Centers for Medicare and Medicaid Services payment schedule \[[@CIT0028]\]. Injection site reactions were assumed to incur no financial costs, and serious adverse events due to the vaccine had costs estimated per dose, with productivity costs due to HZ stratified by severity \[[@CIT0024]\]. Utility estimates were obtained from multiple sources \[[@CIT0024], [@CIT0029]\]. QALYs were adjusted for age based on estimates of US QALYs for noninstitutionalized adults utilizing 7 health-related quality-of-life scores \[[@CIT0030]\]. Mortality rates due to HZ were obtained from the CDC WONDER online database \[[@CIT0031]\].

Sensitivity analyses were performed to assess assumptions and methodological uncertainties by varying the age at vaccination, the waning rate, efficacy, adherence to the second SUV dose, and other variables. Both 1-way and 2-way sensitivity analyses were performed.

RESULTS {#s2}
=======

For the base case analysis ([Table 2](#T2){ref-type="table"}), a strategy of NoV with a cohort entering the model at age 50, 60, and 70 years of age resulted in 31.3%, 26.2%, and 19.7% of individuals developing HZ, respectively. Administration of LAV at these ages resulted in absolute HZ lifetime cumulative incidence reductions of 3.3%, 3.9%, and 1.9%, respectively, whereas SUV had greater reductions at 6.5%, 7.9%, and 8.1%, respectively. Similarly, PHN developed in 3.8%, 3.8%, and 3.6% of people entering the model at age 50, 60, and 70 years, with absolute PHN lifetime cumulative incidence reduced by 0.1%, 0.3%, and 0.4% for LAV, and 0.3%, 0.8%, and 1.5% for SUV, respectively. As a validation of the model, the cumulative lifetime incidence of HZ and PHN are similar to those found in the literature ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

###### 

Lifetime Costs and Effectiveness of NoV vs LAV vs SUV Among Persons Aged 50, 60, and 70 Years With LAV Priced at \$134 and SUV Priced at \$204

  Age at Vaccination, y   Strategy   HZ Cases, %   HZ Cases Prevented vs NoV, %   PHN Cases, %   PHN Cases Prevented vs NoV, %   Total Cost, \$   Incremental Cost vs NoV, \$   QALYs    Incremental QALYs vs NoV   ICER vs NoV, \$/QALY
  ----------------------- ---------- ------------- ------------------------------ -------------- ------------------------------- ---------------- ----------------------------- -------- -------------------------- ----------------------
  50                      NoV        31.28                                        3.85                                           519.06                                         16.047                              
                          LAV        27.99         3.29                           3.71           0.14                            602.64           83.58                         16.047   0.000705                   118 535
                          SUV        24.82         6.47                           3.54           0.31                            630.29           111.24                        16.048   0.001220                   91 156
  60                      NoV        26.24                                        3.82                                           540.16                                         12.801                              
                          LAV        22.35         3.89                           3.51           0.31                            602.09           61.93                         12.802   0.001450                   42 712
                          SUV        18.34         7.90                           3.03           0.79                            599.05           58.90                         12.804   0.003052                   19 300
  70                      NoV        19.70                                        3.65                                           509.19                                         9.267                               
                          LAV        17.76         1.94                           3.29           0.36                            600.40           91.21                         9.268    0.001034                   88 251
                          SUV        11.63         8.07                           2.15           1.49                            516.78           7.59                          9.273    0.005392                   1407

Abbreviations: ICER, incremental cost-effectiveness ratio; LAV, live attenuated herpes zoster vaccine; NoV, no vaccine; PHN, post-herpetic neuralgia; QALY, quality-adjusted life-year, SUV, subunit vaccine.

The utility benefits for 1 million adults vaccinated with LAV at ages 50, 60, and 70 years were 705, 1450, and 1034 QALYs saved, and for SUV, the QALYs saved were 1220, 3052, and 5392, respectively. At a price of \$134.16 for LAV and total SUV price for both doses of \$204.38, incremental costs for LAV and SUV vs NoV were estimated at \$84 and \$111 for an adult aged 50 years, \$62 and \$59 for an adult aged 60 years, and \$91 and \$8 for an adult aged 70 years at vaccination, respectively.

The ICERs for LAV vs NoV at age 50, 60, and 70 years are \$118 535, \$42 712, and \$88 251 per QALY, respectively ([Table 2](#T2){ref-type="table"}). This nonlinear behavior stems from the low risk of HZ at age 50 and the short duration of protection with the vaccine, which leads to a high cost-effectiveness ratio at age 50, but the lack of initial efficacy at older ages leads to a high cost-effectiveness ratio at age 70. For SUV, the corresponding ICER for each age group compared with NoV is \$91 156, \$19 300, and \$1407 per QALY, respectively. [Figure 2](#F2){ref-type="fig"} consists of cost-effectiveness planes for individuals aged 50, 60, and 70 years. The plane for the first age group ([Figure 2A](#F2){ref-type="fig"}) is notable for SUV demonstrating extended dominance over LAV; for the older age groups ([Figure 2B](#F2){ref-type="fig"} and [C](#F2){ref-type="fig"}), LAV has fewer QALYs saved at a higher incremental cost than SUV, indicating that LAV is dominated by SUV. [Figure 3](#F3){ref-type="fig"} demonstrates higher ICERs for LAV vs SUV compared with no vaccination at all age groups. We used the model to calculate the price of SUV that would result in achieving willingness-to-pay thresholds from \$50 000 to \$100 000 per QALY for vaccination at age 50, 60, and 70 years vs the NoV strategy ([Table 3](#T3){ref-type="table"}). At the FDA-approved and ACIP-recommended age of vaccination of 50 years, SUV would be cost-effective at a total price for both doses of \$153 for a willingness-to-pay threshold of \$50 000 per QALY and at \$216 for a willingness-to-pay threshold of \$100 000 per QALY. The price for these ICER thresholds is substantially higher the older the age at vaccination.

###### 

SUV Price to Achieve ICER Target Relative to NoV

  Age   Willingness-to-Pay Threshold, \$   SUV Price to Achieve Willingness-to-Pay Threshold, \$/QALY
  ----- ---------------------------------- ------------------------------------------------------------
  50    50 000                             152.65
        75 000                             184.07
        100 000                            215.50
  60    50 000                             300.88
        75 000                             379.46
        100 000                            458.04
  70    50 000                             474.25
        75 000                             613.09
        100 000                            751.93

Abbreviations: ICER, incremental cost-effectiveness ratio; NoV, no vaccine; QALY, quality-adjusted life-year, SUV, subunit vaccine.

![Cost-effectiveness planes for SUV at different costs, LAV and no vaccination. Abbreviations: LAV, live attenuated herpes zoster vaccine; QALY, quality-adjusted life-year, SUV, subunit vaccine.](ofz219f0002){#F2}

![ICERs vs no vaccination varied by age at vaccination. Abbreviations: ICER, incremental cost-effectiveness ratio; LAV, live attenuated herpes zoster vaccine; QALY, quality-adjusted life-year, SUV, subunit vaccine.](ofz219f0003){#F3}

One-way sensitivity analysis of multiple factors is found in [Table 4](#T4A){ref-type="table"} for age of vaccination of 50 years, 60 years, and 70 years. Notably, the long-term effectiveness of the vaccine (how quickly effectiveness wanes) is a strong driver of cost-effectiveness. If the SUV efficacy waning rate is --0.072 per year, vaccinating 60-year-olds would have an ICER of \$55 082 per QALY, but if SUV wanes more slowly at --0.037 per year, vaccinating 60-year-olds would actually result in cost savings. An additional 1-way analysis of the percentage receiving the second SUV dose by age is found in [Figure 4](#F4){ref-type="fig"}, with assumptions including that a single SUV dose is only 80% as effective as 2 doses initially and that 1 dose had an efficacy waning rate of --0.08 per year (resulting in lost efficacy by 10 years). For those vaccinated at age 50 years ([Figure 4A](#F4){ref-type="fig"}), \~90% must adhere to the second dose for LAV to maintain its cost-effectiveness advantage over SUV; however, only \~50% of 60-year-old vaccine recipients ([Figure 4B](#F4){ref-type="fig"}) need to adhere to maintain the advantage, and by age 70 years ([Figure 4C](#F4){ref-type="fig"}), the cost-effectiveness advantage is maintained regardless of adherence rate.

###### 

One-way Sensitivity Analysis (Impact on ICER for Those Vaccinated at Age 50)

  Variable                                                                 Base Case Value   Range (Low--High)      ICER of LAV vs NoV (Low)   ICER of LAV vs NoV (High)   ICER of UV vs NoV (Low)   ICER of UV vs NoV (High)
  ------------------------------------------------------------------------ ----------------- ---------------------- -------------------------- --------------------------- ------------------------- --------------------------
  HZ incidence per 1000 person-years                                                                                                                                                                 
   50--59 y                                                                6.74              6.66 to 6.82           \$122 293                  \$114 944                   \$93 947                  \$88 476
   60--69 y                                                                9.32              9.20 to 9.44           \$119 128                  \$117 947                   \$92 398                  \$89 937
   70--79 y                                                                12.02             11.79 to 12.25         \$118 535                  \$118 535                   \$91 156                  \$91 156
   80--100 y                                                               12.78             12.49 to 13.07         \$118 535                  \$118 535                   \$91 156                  \$91 156
  Complications given HZ, %                                                                                                                                                                          
   Probability of ocular complications                                                                                                                                                               
    50--59 y                                                               0.03              0.00 to 0.05           \$118 535                  \$118 535                   \$91 156                  \$91 156
    60--69 y                                                               0.04              0.02 to 0.06           \$118 535                  \$118 535                   \$91 156                  \$91 156
    70--79 y                                                               0.05              0.03 to 0.07           \$118 535                  \$118 535                   \$91 156                  \$91 156
    80--100 y                                                              0.07              0.05 to 0.09           \$118 535                  \$118 535                   \$91 156                  \$91 156
   PHN by age                                                                                                                                                                                        
    50--59 y                                                               0.038             0.023 to 0.053         \$147 097                  \$98 262                    \$111 284                 \$76 338
    60--69 y                                                               0.069             0.042 to 0.096         \$124 608                  \$112 953                   \$104 309                 \$80 523
    70--100 y                                                              0.185             0.142 to 0.228         \$118 535                  \$118 535                   \$91 156                  \$91 156
   Probability of moderate or severe PHN                                                                                                                                                             
    50--59 y                                                               0.46              0.36 to 0.56           \$125 132                  \$112 582                   \$95 711                  \$87 001
    60--69 y                                                               0.56              0.46 to 0.66           \$119 950                  \$117 153                   \$93 971                  \$88 499
    70--79 y                                                               0.61              0.51 to 0.71           \$118 535                  \$118 535                   \$91 156                  \$91 156
    80--84 y                                                               0.65              0.55 to 0.75           \$118 535                  \$118 535                   \$91 156                  \$91 156
    85--100 y                                                              0.68              0.58 to 0.78           \$118 535                  \$118 535                   \$91 156                  \$91 156
  Probability of moderate PHN in individuals with moderate or severe PHN   0.5               0.03 to 0.08           \$113 217                  \$127 477                   \$86 068                  \$99 955
  Probability of pain given HZ                                                                                                                                                                       
   No pain given HZ                                                        0.05              0.00 to 0.27           \$12 545                   \$103 649                   \$94 460                  \$79 034
   Mild pain given HZ                                                      0.11              0.04 to 0.43           \$131 068                  \$82 868                    \$101 579                 \$62 354
   Moderate pain given HZ                                                  0.37              0.19 to 0.57           \$134 138                  \$103 522                   \$104 586                 \$78 449
   Severe pain given HZ                                                    0.47              0.26 to 0.63           \$141 224                  \$98 034                    \$111 358                 \$73 277
  Death due to HZ per 100 000                                                                                                                                                                        
   50--59 y                                                                1.26              0.86 to 1.67           \$118 774                  \$118 292                   \$91 320                  \$90 989
   60--69 y                                                                2.22              1.72 to 2.72           \$118 567                  \$118 504                   \$91 215                  \$91 097
   70--79 y                                                                6.18              5.32 to 7.03           \$118 535                  \$118 535                   \$91 156                  \$91 156
   80--89 y                                                                23.96             21.88 to 26.03         \$118 535                  \$118 535                   \$91 156                  \$91 156
   90--100 y                                                               152.13            143.76 to 160.5        \$118 535                  \$118 535                   \$91 156                  \$91 156
  Vaccination efficacy and adverse events                                                                                                                                                            
   LAV efficacy (take)                                                                                                                                                                               
    50--59 y                                                               0.698             0.489 to 0.907         Dominated                  \$21 980                    \$91 156                  \$91 156
   LAV waning rate (reduction in efficacy per year)                        --0.0544          --0.072 to --0.037     \$289 148                  \$38 318                    \$91 156                  \$91 156
   SUV efficacy (take)                                                                                                                                                                               
    Aged 50--59 y                                                          0.969             0.906 to 0.994         \$118 535                  \$118 535                   \$148 649                 \$76 381
  SUV waning rate (reduction in efficacy per year)                         --0.0544          --0.072 to --0.037     \$118 535                  \$118 535                   \$279 166                 \$19 330
   Adverse events above placebo                                                                                                                                                                      
    LAV injection site reaction                                            0.317             0.283 to 0.326         \$118 535                  \$118 535                   \$91 156                  \$91 156
    LAV serious adverse event                                              0.001             0 to 0.002             \$118 535                  \$118 535                   \$91 156                  \$91 156
    SUV injection site reaction                                            0.669             0.6021 to 0.7359       \$118 535                  \$118 535                   \$79 783                  \$106 311
    SUV serious adverse event                                              0.00058           0 to 0.003             \$118 535                  \$118 535                   \$90 321                  \$94 831
  Utilities                                                                                                                                                                                          
   Acute HZ QALYs lost                                                                                                                                                                               
    No pain HZ                                                             0.02              0.014 to 0.026         \$119 726                  \$117 368                   \$92 139                  \$90 194
    Mild HZ                                                                0.041             0.029 to 0.053         \$124 327                  \$113 259                   \$95 953                  \$86 816
    Moderate HZ                                                            0.047             0.033 to 0.061         \$142 874                  \$101 282                   \$111 548                 \$77 067
    Severe HZ                                                              0.058             0.040 to 0.075         \$161 894                  \$93 495                    \$127 923                 \$70 806
   PHN QALYs lost                                                                                                                                                                                    
    Mild pain PHN                                                          0.31              0.211 to 0.433         \$123 419                  \$112 981                   \$95 483                  \$86 297
    Moderate pain PHN                                                      0.55              0.389 to 0.731         \$123 993                  \$112 946                   \$96 430                  \$85 876
    Severe pain PHN                                                        0.77              0.498 to 0.992         \$130 683                  \$110 177                   \$103 058                 \$83 304
   Ocular complications QALYs lost                                         0.24              0.178 to 0.311         \$118 535                  \$118 535                   \$91 156                  \$91 156
   Adverse reactions and adverse events                                                                                                                                                              
    Common AR QALYs lost per dose                                          0.001             0.0005 to 0.002        \$74 809                   Dominated                   \$53 222                  Dominated
    Serious AE QALYs lost per dose                                         0.0000213         6.4E-06 to 4.6E-05     \$116 507                  \$122 016                   \$90 631                  \$92 029
  Costs                                                                                                                                                                                              
   LAV                                                                     \$134.16          \$100.62 to \$167.70   \$72 353                   \$164 718                   \$91 156                  \$91 156
    SUV                                                                    \$204.38          \$153.29 to \$255.48   \$118 535                  \$118 535                   \$50 509                  \$131 812
   Vaccine administration cost (HCPCS 90471)                               \$20.88           \$15.66 to \$26.10     \$111 348                  \$125 723                   \$83 037                  \$99 275
   Direct medical costs, \$/case, adjusted for inflation                                                                                                                                             
    Acute HZ                                                               \$957             \$867 to \$1151        \$122 257                  \$114 648                   \$95 167                  \$86 967
    PHN                                                                    \$5831            \$4055 to \$7936       \$121 582                  \$114 925                   \$94 808                  \$86 828
    Ocular complications                                                   \$4163            \$2986 to \$5543       \$118 535                  \$118 535                   \$91 156                  \$91 156
   Serious adverse event, \$/vaccine dose                                  \$0.18            \$0.11 to \$0.25       \$118 439                  \$118 632                   \$91 124                  \$91 188
   Productivity costs HZ, h                                                                                                                                                                          
    No pain HZ                                                             5                 3 to 5                 \$118 640                  \$118 483                   \$91 268                  \$91 100
    Mild                                                                   6                 4 to 8                 \$120 515                  \$116 555                   \$93 290                  \$89 022
    Moderate HZ                                                            22                15 to 30               \$121 219                  \$115 469                   \$94 048                  \$87 851
    Severe HZ                                                              61                39 to 82               \$129 268                  \$108 290                   \$102 722                 \$80 116
    Mild pain, PHN                                                         4                 3 to 5                 \$118 558                  \$118 513                   \$91 182                  \$91 130
    Moderate pain, PHN                                                     30                20 to 41               \$118 639                  \$118 422                   \$91 285                  \$91 014
    Severe pain, PHN                                                       81                53 to 110              \$118 825                  \$118 235                   \$91 518                  \$90 781
   Average hourly wages, \$                                                \$26.61           \$19.96 to \$33.26     \$129 939                  \$107 132                   \$103 496                 \$78 816

Abbreviations: AE, adverse event; AR, adverse reaction; HCPCS, Healthcare Common Procedure Coding System; HZ, herpes zoster; ICER, incremental cost-effectiveness ratio; LAV, live attenuated HZ vaccine; NoV, no vaccine; PHN, post-herpetic neuralgia; QALY, quality-adjusted life-year, SUV, subunit vaccine.

###### 

One-Way Sensitivity Analysis (Impact on ICER for Those Vaccinated at Age 60)

  Variable                                                                 Base Case Value   Range (Low--High)      ICER of AV vs NoV (Low)   ICER of AV vs NoV (High)   ICER of UV vs NoV (Low)   ICER of UV vs NoV (High)
  ------------------------------------------------------------------------ ----------------- ---------------------- ------------------------- -------------------------- ------------------------- --------------------------
  HZ incidence per 1000 person-years                                                                                                                                                               
   60--69 y                                                                9.32              9.20 to 9.44           \$44 209                  \$41 269                   \$20 125                  \$18 498
   70--79 y                                                                12.02             11.79 to 12.25         \$42 980                  \$42 447                   \$19 795                  \$18 814
   80--100 y                                                               12.78             12.49 to 13.07         \$42 712                  \$42 712                   \$19 300                  \$19 300
  Complications given HZ, %                                                                                                                                                                        
   Probability of ocular complications                                                                                                                                                             
    60--69 y                                                               0.04              0.02 to 0.06           \$42 712                  \$42 712                   \$19 300                  \$19 300
    70--79 y                                                               0.05              0.03 to 0.07           \$42 712                  \$42 712                   \$19 300                  \$19 300
    80--100 y                                                              0.07              0.05 to 0.09           \$42 712                  \$42 712                   \$19 300                  \$19 300
   PHN by age                                                                                                                                                                                      
    60--69 y                                                               0.069             0.042 to 0.096         \$58 423                  \$32 254                   \$26 478                  \$14 048
    70--100 y                                                              0.185             0.142 to 0.228         \$44 435                  \$41 080                   \$22 318                  \$16 684
   Probability of moderate or severe PHN                                                                                                                                                           
    60--69 y                                                               0.56              0.46 to 0.66           \$45 391                  \$40 311                   \$20 310                  \$18 372
    70--79 y                                                               0.61              0.51 to 0.71           \$43 260                  \$42 177                   \$20 041                  \$18 604
    80--84 y                                                               0.65              0.55 to 0.75           \$42 712                  \$42 712                   \$19 300                  \$19 300
    85--100 y                                                              0.68              0.58 to 0.78           \$42 712                  \$42 712                   \$19 300                  \$19 300
  Probability of moderate PHN in individuals with moderate or severe PHN   0.5               0.03 to 0.08           \$40 162                  \$47 132                   \$17 845                  \$21 870
  Probability of pain given HZ                                                                                                                                                                     
   No pain given HZ                                                        0.05              0.00 to 0.27           \$43 496                  \$39 588                   \$19 606                  \$18 067
   Mild pain given HZ                                                      0.11              0.04 to 0.43           \$45 148                  \$34 366                   \$20 298                  \$15 802
   Moderate pain given HZ                                                  0.37              0.19 to 0.57           \$46 355                  \$38 839                   \$21 275                  \$17 176
   Severe pain given HZ                                                    0.47              0.26 to 0.63           \$48 808                  \$36 480                   \$23 157                  \$15 299
  Death due to HZ per 100 000                                                                                                                                                                      
   60--69 y                                                                2.22              1.72 to 2.72           \$42 712                  \$42 712                   \$19 300                  \$19 300
   70--79 y                                                                6.18              5.32 to 7.03           \$42 762                  \$42 663                   \$19 317                  \$19 283
   80--89 y                                                                23.96             21.88 to 26.03         \$42 718                  \$42 707                   \$19 306                  \$19 294
   90--100 y                                                               152.13            143.76 to 160.5        \$42 712                  \$42 712                   \$19 300                  \$19 300
  Vaccination efficacy and adverse events                                                                                                                                                          
   LAV                                                                                                                                                                                             
    60--69 y                                                               0.657             0.460 to 0.854         \$334 733                 \$682                      \$19 300                  \$19 300
   LAV waning rate                                                         --0.0544          --0.072 to --0.037     \$90 956                  \$8690                     \$19 300                  \$19 300
   SUV                                                                                                                                                                                             
    Aged 60--69 y                                                          0.941             0.856 to 0.981         \$42 712                  \$42 712                   \$40 084                  \$12 720
  SUV waning rate                                                          --0.0544          --0.072 to --0.037     \$42 712                  \$42 712                   \$55 082                  Cost-saving
   Adverse events above placebo                                                                                                                                                                    
    LAV injection site reaction                                            0.317             0.283 to 0.326         \$42 712                  \$42 712                   \$19 300                  \$19 300
    LAV serious adverse event                                              0.001             0 to 0.002             \$42 712                  \$42 712                   \$19 300                  \$19 300
    SUV injection site reaction                                            0.669             0.6021 to 0.7359       \$42 712                  \$42 712                   \$18 286                  \$20 432
    SUV serious adverse event                                              0.00058           0 to 0.003             \$42 712                  \$42 712                   \$19 203                  \$19 714
  Utilities                                                                                                                                                                                        
   Acute HZ QALYs lost                                                                                                                                                                             
    No pain HZ                                                             0.02              0.014 to 0.026         \$42 953                  \$42 474                   \$19 399                  \$19 202
    Mild HZ                                                                0.041             0.029 to 0.053         \$43 865                  \$41 619                   \$19 774                  \$18 848
    Moderate HZ                                                            0.047             0.033 to 0.061         \$47 255                  \$38 967                   \$21 153                  \$17 745
    Severe HZ                                                              0.058             0.040 to 0.075         \$50 316                  \$37 105                   \$22 383                  \$16 963
   PHN QALYs lost                                                                                                                                                                                  
    Mild pain PHN                                                          0.31              0.211 to 0.433         \$44 242                  \$40 954                   \$20 043                  \$18 450
    Moderate pain PHN                                                      0.55              0.389 to 0.731         \$45 214                  \$40 211                   \$20 586                  \$18 033
    Severe pain PHN                                                        0.77              0.498 to 0.992         \$48 363                  \$38 994                   \$22 233                  \$17 424
   Ocular complications QALYs lost                                         0.24              0.178 to 0.311         \$42 712                  \$42 712                   \$19 300                  \$19 300
   Adverse reactions and adverse events                                                                                                                                                            
    Common AR QALYs lost per dose                                          0.001             0.0005 to 0.002        \$33 464                  \$95 504                   \$15 112                  \$43 299
    Serious AE QALYs lost per dose                                         0.0000213         6.4E-06 to 4.6E-05     \$42 364                  \$43 296                   \$19 257                  \$19 371
  Costs                                                                                                                                                                                            
   LAV                                                                     \$134.16          \$100.62 to \$167.70   \$20 253                  \$65 171                   \$19 300                  \$19 300
   SUV                                                                     \$204.38          \$153.29 to \$255.48   \$42 712                  \$42 712                   \$3046                    \$35 557
   Vaccine administration cost (HCPCS 90471)                               \$20.88           \$15.66 to \$26.10     \$39 217                  \$46 208                   \$16 053                  \$22 547
   Direct medical costs, \$/case, adjusted for inflation                                                                                                                                           
    Acute HZ                                                               \$957             \$867 to \$1151        \$44 873                  \$40 455                   \$21 283                  \$17 228
    PHN                                                                    \$5831            \$4055 to \$7936       \$46 035                  \$38 774                   \$23 017                  \$14 895
    Ocular complications                                                   \$4163            \$2986 to \$5543       \$42 712                  \$42 712                   \$19 300                  \$19 300
   Serious adverse event, \$/vaccine dose                                  \$0.18            \$0.11 to \$0.25       \$42 666                  \$42 759                   \$19 287                  \$19 313
   Productivity costs HZ, h                                                                                                                                                                        
    No pain HZ                                                             5                 3 to 5                 \$42 773                  \$42 682                   \$19 356                  \$19 272
    Mild                                                                   6                 4 to 8                 \$43 862                  \$41 563                   \$20 355                  \$18 245
    Moderate HZ                                                            22                15 to 30               \$44 270                  \$40 932                   \$20 730                  \$17 666
    Severe HZ                                                              61                39 to 82               \$48 944                  \$36 764                   \$25 020                  \$13 840
    Mild pain, PHN                                                         4                 3 to 5                 \$42 733                  \$42 692                   \$19 322                  \$19 278
    Moderate pain, PHN                                                     30                20 to 41               \$42 847                  \$42 565                   \$19 453                  \$19 131
    Severe pain, PHN                                                       81                53 to 110              \$43 088                  \$42 323                   \$19 730                  \$18 855
  Average hourly wages                                                     \$26.61           \$19.96 to \$33.26     \$49 546                  \$35 879                   \$25 660                  \$12 940

Abbreviations: AE, adverse event; AR, adverse reaction; HCPCS, Healthcare Common Procedure Coding System; HZ, herpes zoster; ICER, incremental cost-effectiveness ratio; LAV, live attenuated HZ vaccine; NoV, no vaccine; PHN, post-herpetic neuralgia; QALY, quality-adjusted life-year, SUV, subunit vaccine.

###### 

One-Way Sensitivity Analysis (Impact on ICER for Those Vaccinated at Age 70)

  Variable                                                                  Base Case Value   Range (Low--High)      ICER of AV vs NoV (Low)   ICER of LAV vs NoV (High)   ICER of SUV vs NoV (Low)   ICER of SUV vs NoV (High)
  ------------------------------------------------------------------------- ----------------- ---------------------- ------------------------- --------------------------- -------------------------- ---------------------------
  HZ incidence per 1000 person-years                                                                                                                                                                  
   70--79 y                                                                 12.02             11.79 to 12.25         \$92 457                  \$84 319                    \$2149                     \$697
   80--100 y                                                                12.78             12.49 to 13.07         \$88 251                  \$88 251                    \$1559                     \$1257
  Complications given HZ, %                                                                                                                                                                           
   Probability of ocular complications                                                                                                                                                                
    70--79 y                                                                0.05              0.03 to 0.07           \$88 251                  \$88 251                    \$1407                     \$1407
    80--100 y                                                               0.07              0.05 to 0.09           \$88 251                  \$88 251                    \$1407                     \$1407
   PHN by age                                                                                                                                                                                         
    70--100 y                                                               0.185             0.142 to 0.228         \$125 194                 \$66 297                    \$6394                     Cost-saving
   Probability of moderate or severe PHN                                                                                                                                                              
    70--79 y                                                                0.61              0.51 to 0.71           \$99 717                  \$79 072                    \$1800                     \$1066
    80--84 y                                                                0.65              0.55 to 0.75           \$88 251                  \$88 251                    \$1465                     \$1351
    85--100 y                                                               0.68              0.58 to 0.78           \$88 251                  \$88 251                    \$1414                     \$1401
   Probability of moderate PHN in individuals with moderate or severe PHN   0.5               0.03 to 0.08           \$79 649                  \$105 022                   \$953                      \$2235
  Probability of pain given HZ                                                                                                                                                                        
    No pain given HZ                                                        0.05              0.00 to 0.27           \$89 400                  \$83 536                    \$1405                     \$1420
    Mild pain given HZ                                                      0.11              0.04 to 0.43           \$91 716                  \$75 425                    \$1448                     \$1251
    Moderate pain given HZ                                                  0.37              0.19 to 0.57           \$92 750                  \$83 277                    \$1958                     \$784
    Severe pain given HZ                                                    0.47              0.26 to 0.63           \$94 971                  \$81 042                    \$2885                     Cost-saving
  Death due to HZ per 100 000                                                                                                                                                                         
    70--79 y                                                                6.18              5.32 to 7.03           \$88 352                  \$88 153                    \$1408                     \$1407
    80--89 y                                                                23.96             21.88 to 26.03         \$88 251                  \$88 251                    \$1408                     \$1407
    90--100 y                                                               152.13            143.76 to 160.5        \$88 251                  \$88 251                    \$1407                     \$1407
  Vaccination efficacy and adverse events                                                                                                                                                             
  LAV                                                                                                                                                                                                 
    70--79 y                                                                0.407             0.285 to 0.529         \$616 280                 \$27 345                    \$1407                     \$1407
  LAV waning rate                                                           --0.0544          --0.072 to --0.037     \$147 990                 \$44 236                    \$1407                     \$1407
  SUV                                                                                                                                                                                                 
    Aged 70--79 y                                                           0.899             0.846 to 0.937         \$88 251                  \$88 251                    \$6236                     Cost-saving
  SUV waning rate                                                           --0.0544          --0.072 to --0.037     \$88 251                  \$88 251                    \$11 242                   Cost-saving
  Adverse events above placebo                                                                                                                                                                        
  LAV injection site reaction                                               0.317             0.283 to 0.326         \$88 251                  \$88 251                    \$1407                     \$1407
    LAV serious adverse event                                               0.001             0 to 0.002             \$88 251                  \$88 251                    \$1407                     \$1407
    SUV injection site reaction                                             0.669             0.6021 to 0.7359       \$88 251                  \$88 251                    \$1367                     \$1451
    SUV serious adverse event                                               0.00058           0 to 0.003             \$88 251                  \$88 251                    \$1385                     \$1501
  Utilities                                                                                                                                                                                           
   Acute HZ QALYs lost                                                                                                                                                                                
     No pain HZ                                                             0.02              0.014 to 0.026         \$88 599                  \$87 906                    \$1412                     \$1403
    Mild HZ                                                                 0.041             0.029 to 0.053         \$89 906                  \$86 656                    \$1427                     \$1389
    Moderate HZ                                                             0.047             0.033 to 0.061         \$94 620                  \$82 686                    \$1481                     \$1341
    Severe HZ                                                               0.058             0.040 to 0.075         \$98 695                  \$79 806                    \$1527                     \$1306
  PHN QALYs lost                                                                                                                                                                                      
    Mild pain PHN                                                           0.31              0.211 to 0.433         \$93 114                  \$82 874                    \$1463                     \$1344
    Moderate pain PHN                                                       0.55              0.389 to 0.731         \$97 963                  \$79 402                    \$1520                     \$1300
    Severe pain PHN                                                         0.77              0.498 to 0.992         \$111 620                 \$75 372                    \$1668                     \$1249
  Ocular complications QALYs lost                                           0.24              0.178 to 0.311         \$88 251                  \$88 251                    \$1407                     \$1407
  Adverse reactions and adverse events                                                                                                                                                                
    Common AR QALYs lost per dose                                           0.001             0.0005 to 0.002        \$64 445                  \$337 906                   \$1225                     \$2007
    Serious AE QALYs lost per dose                                          0.0000213         6.4E-06 to 4.6E-05     \$87 291                  \$89 871                    \$1406                     \$1410
  Costs                                                                                                                                                                                               
  LAV                                                                       \$134.16          \$100.62 to \$167.70   \$56 744                  \$119 758                   \$1407                     \$1407
  SUV                                                                       \$204.38          \$153.29 to \$255.48   \$88 251                  \$88 251                    Cost-saving                \$10 609
  Vaccine administration cost (HCPCS 90471)                                 \$20.88           \$15.66 to \$26.10     \$83 348                  \$93 155                    Cost-saving                \$3245
  Direct medical costs, \$/case, adjusted for inflation                                                                                                                                               
    Acute HZ                                                                \$957             \$867 to \$1151        \$89 834                  \$86 599                    \$2582                     \$180
    PHN                                                                     \$5831            \$4055 to \$7936       \$94 028                  \$81 404                    \$5696                     -\$3676
    Ocular complications                                                    \$4163            \$2986 to \$5543       \$88 251                  \$88 251                    \$1407                     \$1407
  Serious adverse event, \$/vaccine dose                                    \$0.18            \$0.11 to \$0.25       \$88 185                  \$88 317                    \$1400                     \$1415
  Productivity costs HZ, h                                                                                                                                                                            
    No pain HZ                                                              5                 3 to 5                 \$88 296                  \$88 229                    \$1440                     \$1391
    Mild                                                                    6                 4 to 8                 \$89 093                  \$87 410                    \$2033                     \$782
    Moderate HZ                                                             22                15 to 30               \$89 392                  \$86 948                    \$2255                     \$439
    Severe HZ                                                               61                39 to 82               \$92 815                  \$83 895                    \$4796                     Cost-saving
    Mild pain, PHN                                                          4                 3 to 5                 \$88 283                  \$88 219                    \$1431                     \$1384
    Moderate pain, PHN                                                      30                20 to 41               \$88 501                  \$87 976                    \$1595                     \$1201
    Severe pain, PHN                                                        81                53 to 110              \$88 951                  \$87 526                    \$1933                     \$864
  Average hourly wages                                                      \$26.61           \$19.96 to \$33.26     \$93 694                  \$82 809                    \$5453                     Cost-saving

Abbreviations: AE, adverse event; AR, adverse reaction; HCPCS, Healthcare Common Procedure Coding System; HZ, herpes zoster; ICER, incremental cost-effectiveness ratio; LAV, live attenuated HZ vaccine; NoV, no vaccine; PHN, post-herpetic neuralgia; QALY, quality-adjusted life-year, SUV, subunit vaccine.

![One-way analysis of adherence to second SUV dose. Abbreviations: ICER, incremental cost-effectiveness ratio; LAV, live attenuated herpes zoster vaccine; NoV, no vaccine; QALY, quality-adjusted life-year, SUV, subunit vaccine.](ofz219f0004){#F4}

Two-way sensitivity analysis shows that both waning and age at vaccination can be important to the cost-effectiveness of the SUV ([Table 5](#T5){ref-type="table"}). If the vaccine waning rate is high (7.2%) and 50-year-olds are vaccinated, the ICER is \$279 166 per QALY. But if the vaccine waning rate is low (3.7% per year) and 60-year-olds are vaccinated, the vaccine is cost-saving. [Supplementary Table 2](#sup1){ref-type="supplementary-material"} has an additional threshold analysis on the waning efficacy of SUV.

###### 

Two-Way Sensitivity Analysis on Age and SUV Waning

                              Age at Immunization, y                                                         
  ----------------- --------- ------------------------ ----------- ------------- ------------- ------------- -------------
  SUV waning rate   --0.072   \$279 166                \$128 762   \$55 082      \$25 350      \$11 242      \$14 271
                    --0.065   \$176 504                \$90 444    \$38 576      \$17 130      \$7180        \$10 266
                    --0.058   \$113 844                \$59 093    \$25 230      \$10 026      \$3304        \$6505
                    --0.051   \$73 511                 \$35 805    \$14 233      \$3804        Cost-saving   \$3043
                    --0.044   \$42 451                 \$18 259    \$5204        Cost-saving   Cost-saving   Cost-saving
                    --0.037   \$19 381                 \$5239      Cost-saving   Cost-saving   Cost-saving   Cost-saving

Abbreviations: ICER, incremental cost-effectiveness ratio; NoV, no vaccine; SUV, subunit vaccine.

The probabilistic sensitivity analysis ([Figure 5](#F5){ref-type="fig"}) also suggests that SUV is highly likely to be cost-effective for a weighted average of ages from 50 to 70 years. It is 69% likely to be cost-effective at an ICER of \$50 000 per QALY and 82% likely to be cost-effective at an ICER of \$150 000 per QALY.

![Probabilistic sensitivity analysis: cost-effectiveness acceptability curves. Abbreviations: LAV, live attenuated herpes zoster vaccine; NoV, no vaccine; SUV, subunit vaccine.](ofz219f0005){#F5}

DISCUSSION {#s3}
==========

This CEA demonstrates that for many cost and age at vaccination scenarios, SUV is likely to offer very good value in comparison to an NoV strategy. In most of these scenarios, SUV demonstrates dominance over the currently available LAV. Although LAV has an indication for persons aged 50 years and above, it is only recommended by the ACIP for persons aged 60 years and above due to diminished cost-effectiveness. In contrast, SUV received both an FDA indication and an ACIP recommendation for persons aged 50 and above, with our study and others demonstrating its value for individuals aged 50 to 60 years \[[@CIT0009], [@CIT0020]\]. Targeting persons aged 60 years and above (similar to LAV), SUV appears much more cost-effective, and remains so even with unfavorable variation in its estimated waning rate.

The results of our analysis are very consistent with the analyses by Le et al. \[[@CIT0014]\] and Prosser \[[@CIT0019]\], as well as the GSK analysis subsequently published by Curran et al. \[[@CIT0021]\], despite differences in model structure, assumptions, and inputs. Our model had slightly different functional forms and parameterization for vaccine effectiveness and how PHN affects patients. All 4 analyses found SUV to be cost-effective compared with LAV for the age groups studied. The cost per QALY was in general highest in the youngest age groups, where the incidence of HZ and PHN was the lowest. All models were sensitive to a number of inputs, including vaccine efficacy, age at vaccination, vaccine waning rate, and completion rates for the second dose of SUV. Unlike the studies by Le et al. \[[@CIT0014]\] and Curran et al. \[[@CIT0021]\], our analysis examines the cost-effectiveness of SUV for a younger population aged 50 and finds that SUV could be cost-effective for that population.

There are several limitations to our analysis. Perhaps most significant is the assumption that the waning rate of SUV is comparable to LAV. As noted, few data on this assumption are available; however, the waning rate for SUV is unlikely to be significantly faster than that of LAV based on results extending to 4 years for the ZOE-70 and ZOE-50 trials \[[@CIT0009], [@CIT0010]\], and SUV might end up having a significantly slower waning rate than LAV. This assumption is thus more likely to result in an underestimate of the value of SUV.

A second important limitation is the assumption that 95.5% of individuals would return for their second SUV dose, as was observed in the phase 3 trials \[[@CIT0009], [@CIT0010]\]. ISR and the cost of the second dose of the vaccine could result in a lower real-world return rate, resulting in both lower efficacy and lower costs and consequentially mixed ICER variations depending on age at vaccination. As demonstrated in our analysis, when vaccinated at younger ages, adherence to the second dose must be high to maintain cost-effectiveness. At older ages, adherence appears less important from the CEA perspective; however, this older adult population, having more often witnessed the morbidity of HZ and PHN, might be more motivated to adhere to the second dose, regardless of cost or the risk of ISRs. Strategies to optimize adherence will be essential to achieve adherence values at or near those observed in clinical trials \[[@CIT0009], [@CIT0010]\].

Another limitation in the Markov model is that it does not account for the possibility that patients who develop HZ might develop enhanced immunity against redeveloping HZ and PHN; however, this consideration is controversial \[[@CIT0002]\], and if present, the limitation would affect all 3 strategies comparably, and thus it would be less likely to have significant impact in the final comparison. Furthermore, our analysis does not take into account the potential for a reduction of PHN beyond that afforded by the reduction in HZ; without this additional reduction in PHN incidence, we might be overestimating the associated ICERs for each vaccine strategy. Finally, another important limitation is that the model could not account for individuals vaccinated with SUV who had previously received LAV (ACIP recommends SUV regardless of prior LAV vaccination status) \[[@CIT0008]\].

Additional information will be forthcoming on long-term efficacy, as a subgroup of ZOE-50 and ZOE-70 patients are being monitored for continued efficacy of the vaccine beyond the 4-year study periods. In addition, given the information available on the persistence of LAV efficacy, the role of a booster vaccination for LAV should be considered (and depending on the outcome of the persistence studies for SUV, a booster vaccination for SUV might also need to be considered). Furthermore, the role of combining these vaccines (ie, providing both LAV and SUV in an undetermined sequence separated by an undetermined interval) might also deserve study. Unlike LAV, SUV is not a live vaccine \[[@CIT0005], [@CIT0009], [@CIT0010]\], and as such its role in immunocompromised patients is important to study, as this population is generally at even higher risk for HZ and PHN than members of the general population.

In conclusion, immunization of adults aged 50 years and above with SUV appears to be of good value, given the current pricing of SUV and assuming a waning rate comparable to that of LAV. Even at higher prices (especially in older age groups), with faster waning rates, and with poorer adherence to the second dose, our model suggests that SUV remains cost-effective at a willingness-to-pay threshold of \$100 000 per QALY. Forthcoming data on SUV waning rate will allow for a more robust comparison between SUV, LAV, and NoV, and additional studies are required to determine the role of booster doses for these vaccines.
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